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*Streptococcus pneumoniae* is a leading cause of pneumonia and death in children worldwide \[[@CR1]\]. It is estimated that 14.5 million episodes of serious pneumococcal disease occur each year in children aged less than five years, resulting in at least 500,00 deaths, almost all of which occur in low- and middle-income countries \[[@CR2]\]. Vaccination has proved very successful in the control of pneumococcal disease in many developing countries and there is growing evidence for herd protection. For example, in The Gambia, infant vaccination has reduced vaccine-type pneumococcal carriage not only among vaccinated children but also among non-vaccinated older children and adults, indicating a substantial herd effect \[[@CR3]\]. However, not all countries have introduced vaccination of infants as implementation is limited by the high cost of the vaccine \[[@CR4]\]. The cost of one dose of pneumococcal conjugate vaccine (PCV) can be very high in developed countries (\> \$100) \[[@CR5]\]. The best subsidised price for resource-poor countries has been brought down to \$3 · 30 per dose \[[@CR6]\], which is comparable to the cost of all other pediatric vaccines combined (HepB, BCG, OPV, DPT-Hib, and Measles) \[[@CR7]\]. Therefore, there is intense interest in reducing the cost of vaccination against pneumococcal disease in young children through eg. shorter schedules of one or two doses instead of three doses \[[@CR8]\].

The use of the 3 + 0 schedule is supported by randomised controlled clinical trials for prevention of pneumonia and invasive pneumococcal disease (IPD) in developing countries \[[@CR9]\], and has been recommended by WHO. However, after more than a decade of using PCV in many developed countries, evidence consistently demonstrates strong herd immunity; most vaccine-type pneumococcal disease is close to elimination in children irrespective of individual vaccination status \[[@CR10]\]. Consequently, a "1 + 1" schedule (where a booster dose is given in second year of life) has been promoted for use in developing countries where the immunisation program is mature (implemented for few years) and vaccine-type carriage is largely eliminated in the community \[[@CR11]\]. In such mature vaccine programmes, individual protection may not be required because the probability of exposure to vaccine-type infection has become very low \[[@CR10]\]. Therefore, a "1 + 1" schedule could be sufficient to maintain disease control, and at a considerably reduced cost \[[@CR8]\]. Long-term protection against IPD by PCV depends on a combination of persistence of protective serum antibody levels, immunological memory, and herd immunity \[[@CR12]\]. Additionally, and importantly, we suggest consideration of the use of carrier priming to enhance the immunogenicity, especially of the first PCV dose. Carrier priming is defined as an improved antibody response to a carbohydrate portion of a glycoconjugate vaccine because an individual has been previously primed with the carrier protein \[[@CR13]\].

The 13-valent PCV utilises carrier protein cross-reacting material 197 (CRM197) of diphtheria toxin, which is antigenically similar to the diphtheria toxin in DTP. It is believed that priming via the carrier molecule enhances the response to conjugate vaccines by increasing the number of carrier-specific T lymphocytes; these can provide the necessary support for the expansion and differentiation of polysaccharide specific B lymphocytes \[[@CR14]\]. Several studies have found that prior receipt of tetanus/diphtheria containing vaccine such as DTP in infants who are then administered conjugate vaccine can lead to rapid and earlier onset of clinical protection against the disease \[[@CR15]-[@CR17]\]. In developing countries, the risk of IPD peaks in the first few months of life and the current vaccine schedule is 6, 10 and 14 weeks. We propose evaluation of a schedule that offers the first PCV at ten weeks of age after prior administration of DTP vaccine at six weeks to take advantage of carrier priming \[[@CR16]\]. If adequate priming occurs, a reduced schedule (where first PCV is given after DTP) may be sufficient and more cost-effective, particularly for resource poor settings with mature immunisation programs.

BCG

:   Bacille Calmette Guerin vaccine

CRM197

:   Cross-reacting material 197

DPT-Hib

:   Diphtheria tetanus pertussis vaccine and haemophilus influenzae type b vaccine

HepB

:   Hepatitis B vaccine

OPV

:   Oral polio vaccine

IPV

:   Invasive pneumococcal disease

PCV

:   Pneumococcal conjugate vaccine
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